Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II study
Brian Weiss(Cincinnati Children's Hospital Medical Center), Michael J. Fisher(Children's Hospital of Philadelphia), Alan Cantor(Cincinnati Children's Hospital Medical Center), Alexander A. Vinks(Cincinnati Children's Hospital Medical Center), Roger Packer(Children's National), Eva Dombi(National Institutes of Health), David H. Gutmann(Washington University in St. Louis), Elizabeth K. Schorry(Cincinnati Children's Hospital Medical Center), Pamela L. Wolters(National Cancer Center), Brigitte C. Widemann(National Cancer Institute), John P. Perentesis(University of Southern California), Bruce R. Korf(University of Alabama at Birmingham)
Cited by 87
Related Papers
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557
Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force
|Genetics in Medicine|2002|398
Renal Carcinomas With the t(6;11)(p21;q12)
|The American Journal of Surgical Pathology|2005|290
Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1
|American Journal of Medical Genetics|2000|241